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Abstract
Background: Remote ischemic preconditioning (RIPC) efficacy is debated. Possibly, because propofol, which has a
RIPC-inhibiting action, is used in most RIPC trials. It has been suggested that clinical efficacy is, however, present
with volatile anesthesia in the absence of propofol, although this is based on one phase 1 trial only. Therefore, in
the present study we further explore the relation between RIPC and cardioprotection with perioperative anesthesia
restricted to sevoflurane and fentanyl, in CABG patients without concomitant procedures.
Methods: In a single-center study, we aimed to randomize 46 patients to either RIPC (3x5 min inflation of a blood
pressure cuff around the arm) or control treatment (deflated cuff around the arm). Blood samples were obtained
before and after RIPC to evaluate potential RIPC-induced mediators (Interleukin (IL)-6, IL-10, Tumor Necrosis Factor-α,
Macrophage Inhibitory Factor). An atrial tissue sample was obtained at cannulation of the appendix of the right atrium
for determination of mitochondrial bound hexokinase II (mtHKII) and other survival proteins (Akt and AMP-activated
protein kinase α). In blood samples taken before and 6, 12 and 24 h after surgery cardiac troponin T (cTnT) and C-
reactive protein (CRP) were determined. Surgery was strictly performed under sevoflurane anesthesia (no propofol).
Results: We actually randomized 16 patients to control treatment and 13 patients to RIPC. The mean 24 h area under
the curve (AUC) cTnT was 11.44 (standard deviation 4.66) in the control group and 10.90 (standard deviation 4.73) in the
RIPC group (mean difference 0.54, 95% CI −3.06 to 4.13; p = 0.76). The mean 24 h AUC CRP was 1319 (standard deviation
92) in the control group and 1273 (standard deviation 141) in the RIPC group (mean difference 46.2, 95% CI −288 to 380;
p = 0.78). RIPC was without effect on survival proteins in atrial tissue samples obtained before surgery (mitochondrial
hexokinase, Akt and AMPK) and inflammatory mediators obtained before and immediately after RIPC (IL-6, IL-10, TNF-α,
macrophage migration inhibitory factor).
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Conclusion: Many factors can interfere with the outcome of RIPC. Trying to correct for this led to strict inclusion criteria,
which, in combination with a decreased institutional frequency of CABG without concomitant procedures and a change
in institutional anesthetic regimen away from volatile anesthetics towards total intravenous anesthesia, caused slow
inclusion and halting of this trial after 3 years, before target inclusion could be reached. Therefore this study is
underpowered to prove its primary goal that RIPC reduced AUC cTnT by < 25%. Nevertheless, we have shown that the
effect of RIPC on 24 h AUC cTnT, in cardiac surgery with anesthesia during surgery restricted to sevoflurane/fentanyl (no
propofol), was between a decrease of 27% and an increase of 36%. These findings are not in line with previous studies
in this field.
Trial registration: The Netherlands Trial Register: NTR2915; Registered 25 Mei 2011.
Background
Remote ischemic preconditioning (RIPC), the protection
of an organ or tissue against infarction, induced by pre-
vious, repetitive short episodes of ischemia of a remote
organ or tissue, was first discovered by Przyklenk et al.
[1]. Short periods of ischemia and reperfusion in the cir-
cumflex coronary artery preconditioned myocardium
outside of the occluded vasculature. Subsequently, short
periods of ischemia/reperfusion (I/R) in other organs
than the heart immediately prior to the sustained coron-
ary artery occlusion could also induce preconditioning
(reviewed by [2]). Nowadays applying I/R to one of the
limbs is the most used methods of RIPC in clinical stud-
ies (amongst others [3–7]). Results from these studies
are, however, contradictory.
Type of anesthesia employed, comorbidities and co-
medication are factors that have been found to influence
the effect of RIPC [4, 8, 9]. Propofol might counteract the
protective effect of RIPC [4]. In two recent large clinical
trials, no protective effect of RIPC was found [5, 6]. Both
these studies were mainly performed under propofol
anesthesia. Although these studies have been criticized for
their use of propofol in several commentaries and edito-
rials, the establishment of RIPC efficacy with volatile
anesthesia in the absence is not firmly based [10]. For ex-
ample, only one phase 1 trial demonstrated RIPC efficacy
with the volatile anesthetic isoflurane as primary
anesthetic agent (group size varied from 14 to 20 patients)
[4]. However, it is well accepted that positive studies are
prioritized for publication, thus it cannot be excluded that
also for volatile anesthesia RIPC can be ineffective. There-
fore, in the current study we aimed to randomize 46 pa-
tients to either RIPC (3×5 min inflation of a blood
pressure cuff around the arm) or control treatment (de-
flated cuff around the arm) in coronary artery bypass graft
(CABG) procedures with anesthesia restricted to the use
of the volatile anesthetic sevoflurane as primary anesthetic
agent in the absence of propofol. To this end, we evalu-
ated the release of cardiac troponin T (cTnT) as primary
outcome parameter of RIPC efficacy. As secondary read-
out of cardiac damage and RIPC, we examined the
development of systemic inflammation (C-reactive protein
(CRP)). Additionally, it is established that when the
heart is put into a cardioprotective state, this is often
reflected by alteration of specific cardiac, so-called,
survival proteins. Increases in mitochondrial hexoki-
nase (mtHK) [11–15] and in the phosphorylation sta-
tus of Akt (p-Akt) or AMPK (p-AMPK) [16] often
associate with effective cardioprotective interventions.
Therefore, as an additional secondary read-out of
possible RIPC cardioprotective interference, we also
examined whether RIPC affected mitochondrial HKII
protein content (mtHKII) or HK activity, p-Akt or p-
AMPK within the heart. Finally, it has been hypothesized
that RIPC can be mediated through the immediate release
of blood-borne factors mediating the cardioprotective
signaling [16]. To examine whether our RIPC maneuver
was associated with increasing blood-borne factors,
several inflammatory mediators (interleukin (IL)-6, IL-10,
TNF-α, macrophage migration inhibitory factor (MIF))
were measured in blood obtained before and immediately
after RIPC.
Methods
This study was a single-center, randomized controlled
clinical trial in male patients (>18 years) undergoing
elective first time on-pump isolated CABG surgery.
Exclusion criteria were diabetes mellitus, instable angina
pectoris, increased baseline troponin levels, concomitant
procedures, severe COPD, ejection fraction <40%, myo-
cardial infarction within 2 weeks before surgery, periph-
eral vascular disease affecting the upper limbs, women
and nicorandil use. Ticagrelor use was stopped 5 days
before surgery. Clopidogrel, carbasalatecalcium and
aspirin were continued until surgery. In the operating
room, patients were randomized in blocks of 6 to
control or RIPC treatment using a computer program
(ALEA) by the researcher. Patients, anesthetists,
surgeons and Intensive Care Unit (ICU) staff were
blinded to treatment allocation. Samples were in a
blinded manner.
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Study protocol
Patients were pre-medicated with midazolam 7.5 mg per
os. Induction of anesthesia was performed with intraven-
ously (i.v.) applied midazolam 0.1–0.2 mg/kg, i.v. sufenta-
nil 1.0–1.5 μg/kg and i.v. rocuronium 0.6 mg/kg.
Continuous infusion of sufentanil 0.3 μg/kg/h and sevo-
flurane were used for maintenance of hypnosis. No propo-
fol was given until transport to the ICU and during ICU
stay. All patients received routine monitoring, including
ECG, continuous measurement of hemodynamics, capno-
graphy, pulse oximetry, and temperature measurement. A
blood pressure cuff was placed around the patients arm.
Following induction of anesthesia, RIPC was started im-
mediately in the intervention group, by 3 times 5 min in-
flation of the blood pressure cuff to 200 mmHg. During
the RIPC procedure the patient was prepped and the RIPC
procedure was finished before the start of surgery. Surgery
started 13 ± 6 min after the end of the last cuff inflation.
Routine surgical techniques were employed and blood or
cold crystalloid cardioplegia were used. During cannula-
tion of the vena cavae, a tissue probe from the right
atrium was taken and immediately processed. Manage-
ment of the cardiopulmonary bypass was performed ac-
cording to standard procedures. Patients were transported
to the ICU under propofol anesthesia and at the ICU pro-
pofol anesthesia was continued until the patient reached a
core temperature of 36 °C. At the ICU patients started to
received insulin when blood-glucose levels were between
8 and 10 mM for two consecutive measurements. Blood
samples were taken before and 6, 12, 24 and 48 h follow-
ing surgery to determine cTnT and CRP levels. In
addition, blood samples were obtained before and 5 min
after the last RIPC or comparable time points in the con-
trol group for determination of IL-6, IL-10, TNF-α and
MIF (Fig. 1).
Outcomes
Primary outcome in this study was cTnT. Blood was col-
lected by practiced personnel in serum collection tubes
via the venous line when present (during surgery and at
the ICU), or via extra venipuncture. All samples were
immediately analyzed using electrochemiluminescence
technology (Roche modular E170) in the Laboratory of
Clinical Chemistry of the Academic Medical Centre,
Amsterdam, The Netherlands.
Secondary outcome measures were mitochondrial
hexokinase binding and activity after RIPC, Akt and
AMPK phosphorylation after RIPC, CRP levels before
and 6, 12, 24 and 48 h after surgery and MIF, IL-6, IL-10
and TNF-α levels before and after RIPC.
Blood was collected for cTnT and CRP determination
before and 6, 12, 24 and 48 h after surgery. Because
many patients were already transported to other hospi-
tals 48 h after surgery their cTnT and CRP values were
missing. Therefore, we report these values until 24 h
post-surgery.
Initially we planned to determine mitochondrial bind-
ing using electron microscopy. However, the mandatory
extended handling of tissue for EM analysis (storage in
fixative at −80°C and then trying to cut ultrathin section
of 70 nm) resulted that the tissue was severely ruptured
with few and swollen mitochondria. Because for EM
analysis intact tissue with enough intact mitochondria
was necessary, this extended handling of the fragile hu-
man atrial tissue did not lend itself for this kind of ana-
lysis. Therefore, we decided to resort to much simpler
handling of the tissue and determine mitochondrial
HKII binding using western blot. 25 tissue samples have
been processed for western blotting. Because protein
concentration was too low in one of these samples, 24
samples have been used for analysis. Collected tissue
samples were immediately put on ice in homogenization
buffer (pH7.4) containing (mM) sucrose 250, HEPES 20,
KCl 10, MgCl2 1.5 EDTA 1, glucose 5, PMSF 0.1, 5 μg/
ml leupeptin and aprotinin and 1 μg/ml pepstatin and
transported to the laboratory where samples were ho-
mogenized using a Potter homogenizer at 1200/min in
2 mL homogenization buffer. The homogenate was cen-
trifuged for 3 min at 800 g. Part of the supernatant was
stored as whole homogenate. The rest of the supernatant
was centrifuged 10 min at 10 000 g. The resultant pellet
is the mitochondrial fraction and the supernatant is the
cytosolic fraction. All steps were performed at 4 °C.
Fractions were stored at −80 °C until use.
Western blotting of cardiac tissue was performed as
described previously [17, 18]. In short, protein concen-
tration was determined by the Bradford method. Equal
amount of mitochondrial, cytosolic or whole heart hom-
ogenate (15 μg) was loaded on a 4-12% gradient gel
(Biorad), electrophoresed and transferred to a polyvinyli-
dene membrane. Membranes were incubated overnight
with the primary antibodies HKII (1:500; Abcam
104836), phospho-Akt (Ser473) (1:500; Cell Signaling
#9271), Akt (1:1000; Cell Signaling #9272), phospho-
AMPKα (Thr172) (1:1000; Cell Signaling #2535),
AMPKα (1:1000; Cell Signaling #2603) and the mito-
chondrial marker VDAC (1:500; Calbiochem PC548) or
alpha-tubulin (1:40 000; Sigma T9026). Immunoreactive
bands were visualized by the Odyssey system and quan-
tified using the Odyssey IR Manager. All samples were
analyzed on the same blot.
HK activity was determined in all cell fractions using a
spectrophotometric assay at 25 °C with glucose-6-
phosphate dehydrogenase, glucose, ATP and NAD+, in
the presence of rotenone (1 μM) to inhibit mitochon-
drial respiration. Formation of NADH was measured at
340 nm. Citrate synthase (CS) activity was measured at
25 °C using acetyl-CoA, oxaloacetate and di-
Nederlof et al. BMC Anesthesiology  (2017) 17:51 Page 3 of 12
thionitrobenzoic acid, measuring the formation of thio-
nitrobenzoic acid at 412 nm and used as mitochondrial
marker. In cytosolic and homogenate fractions hexoki-
nase activity was corrected for protein concentration.
MIF, IL-6, IL-10 and TNF-α were measured in the
serum samples taken before and after RIPC using ELISA
kits according to the manufacturer’s instructions (all
R&D systems).
Sample size calculation
Sample size calculation in this study is based on the
main study parameter, cardiac protection, evaluated by
cTnT values.
Based on cTnT values obtained by us in a previous
study in CABG patients [19] (area under the curve
(AUC) = 20.3 ± 5.8, α = 0.05 and power = 90%), 2×23 pa-
tients are needed to detect a 25% significant decrease in
AUC for cTnT with RIPC.
Statistical analysis
Data are represented as mean+/− SD or single values
with mean or median. Statistics were performed using
SPSS Version 21. Data was tested for normality. Differ-
ences between groups were tested with a Students’ t-test
(cTnT, CRP, HK activity, pAkt/Akt, MIF) or Mann-
Whitney U test (the amount of mtHKII, pAMPK/
AMPK), depending on normality. Categorical values
were compared using the Chi Squared (two categories)
or Fisher’s exact (more than two categories) test. A Pear-
son correlation coefficient was computed to assess the
Fig. 1 Schematic overview of the study protocol and flowchart for patient enrolment. a A blood pressure cuff was placed around the patients
arm. Following induction of anesthesia a remote ischemic preconditioning was induced immediately in the intervention group, by 3 times 5 min
inflation of the blood pressure cuff to 200 mmHg. Surgery was started 13 ± 6 min after the end of the RIPC protocol. Blood samples (#) were
taken before and after cuff inflation, before the start of surgery, or a comparable time point in control patients. A tissue probe of the right atrium
was taken during cannulation of the vena cavae (*). b Flowchart for patient enrolment
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relationship between cTnT levels and the amount of
mtHKII. Missing values in AUC analysis were
substituted by the group mean. This was the case for 1
value in the control group and 1 in the RIPC group
(control group: t = 6: 1, RIPC group: t = 24: 1). For MIF
ELISA, values below the detection limit were replaced
by the detection limit (12.75 pg/mL). 25 values were re-
placed. Before RIPC 7 in the control group and 4 in the
RIPC group. After RIPC 8 in the control group and 6 in
the RIPC group.
Results
Between March 2012 and April 2015, a total of 663 pa-
tients were screened (Fig. 1b). 562 patients were ex-
cluded because they did not meet inclusion criteria, 6
patients declined to participate and 60 patients were not
included because of other reasons. Other reasons were,
amongst others, that it was not possible to use sevoflur-
ane on the extracorporeal circulation, the patient was
already included in another clinical trial or logistical rea-
sons. 35 patients were randomized, of which 29 could be
included. Patients were excluded because surgery was
performed off-pump (2), propofol was used at induction
of anesthesia (1), increased pre-operative levels of cTnT
(1), concomitant procedures were performed (1) or it
was unable to perform the protocol during surgery (1).
Patient characteristics are presented in Table 1. Intra-
operative data is presented in Table 2. There was no dif-
ference in inotropic support between groups (data not
shown).
Determination of cTnT, representing the primary end-
point of the study, peaked at 6 h after surgery (Fig. 2).
The mean 24 h AUC cTnT was 11.4 (standard deviation
4.66) in the control group and 10.90 (standard deviation
4.73) in the RIPC group (mean difference 0.54, 95% CI
−3.06 to 4.13; p = 0.76). We next evaluated whether our
secondary outcome parameter CRP, indicating the peri-
operative inflammatory response, was affected by RIPC.
CRP continuously rose during the first 24 h following
surgery, indicating the activation of a pro-inflammatory
state with CABG (Fig. 3). The mean 24 h AUC CRP was
1320 (standard deviation 368) in the control group and
1273 (standard deviation 508) in the RIPC group (mean
difference 46, 95% CI −288 to 380; p = 0.78).
Subsequently, possible RIPC effects on protein within
atrial tissue were evaluated. HKII was clearly detectable
in the mitochondrial compartment (see representative
image Fig. 4a). RIPC was without effect on HKII protein
content in the mitochondrial compartment (0.085 ± 0.08
and 0.093 ± 0.13 in control and RIPC group, respect-
ively) (Fig. 4b). In addition we investigated the correl-
ation between the amount of mtHKII and cTnT release.
There was no correlation between the two parameters in
both the control and RIPC group, r = 0.176, p = 0.55 for
control and r = −0.39, p = 0.30 for RIPC (Fig. 4c). We
next evaluated the effect of RIPC on mitochondrial HK
activity (Fig. 4d and e). mtHK activity, either normalized
to mitochondrial protein (Fig. 4d) or to the mitochon-
drial marker enzyme citrate synthase (Fig. 4e), did not
differ between groups (21.7 ± 12.7 and 17.7 ± 12.7 mU/
mg protein and 0.14 ± 0.07 and 0.15 ± 0.08 in control
and RIPC group, respectively).
The survival proteins Akt and AMPK and their phos-
phorylated status were detectable in all samples (repre-
sentative images Fig. 5a and b). RIPC was without effect
on the phosphorylation of AMPK and Akt in atrial tissue
(AMPK: 0.39 ± 0.04 and 0.44 ± 0.10, AKT: 0.22 ± 0.06
and 0.21 ± 0.04 in control and RIPC group, respectively)
(Fig. 5c and d).
IL-6, IL-10 and TNF-α were undetectable in most pa-
tients before and after RIPC (data not shown). We were
able to detect MIF in most patients before and 10 min
after the last occlusion of the upper arm. There was a
large variation in MIF present in the blood, both before
and after RIPC. RIPC was without any detectable effects
on these values (ΔMIF −5.0 ± 33.1 and −10.5 ± 22.7 pg/L
in control and RIPC group, respectively) (Fig. 6).
In this trial, there were no adverse events or deaths re-
lated to the intervention.
Discussion
Due to slow inclusion, resulting from strict inclusion cri-
teria, a change in patient population in our hospital
(much less surgeries without concomitant procedures
were performed than expected) and a change in institu-
tional anesthetic regimen away from volatile anesthetics
towards total intravenous anesthesia (TIVA), this trial
was stopped after 3 years, but before target inclusion
was reached. We have shown that the effect of RIPC on
24 h AUC cTnT was between a decrease of 27% and an
increase of 36%. We cannot exclude that the clinically
significant difference of 25% in our sample size calcula-
tion exists in cardiac surgery with anesthesia restricted
to sevoflurane/fentanyl (no propofol).
Concerning the secondary outcome parameters, we
were unable to show a cardioprotective effect of RIPC in
CABG patients under sevoflurane anesthesia in 24 h
cTnT or CRP release. In addition, no differences in car-
diac mtHKII protein content or mitochondrial HK activ-
ity before bypass were observed between control and
RIPC. RIPC was also without effects on the survival pro-
teins Akt and AMPK. Finally, in this study the RIPC
intervention was not associated with detectable changes
in the plasma cytokines IL-6, IL-10, TNF-α or MIF, im-
mediately following the RIPC protocol, making it un-
likely that these factors are affected by the RIPC
maneuver.
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Table 1 Patient characteristics
All patients Patients with mitochondria samples
Control (n = 16) RIPC n = 13) Control (n = 14) RIPC (n = 10)
Age 66 ± 9.6 70 ± 7.5 67 ± 9.7 71 ± 7.3
Body mass index 27.5 ± 4.1 25.6 ± 2.9 26.9 ± 3.6 25.5 ± 2.6
Euroscore, mean 3.1 ± 1.9 3.8 ± 2.0 3.1 ± 1.4 3.8 ± 2.1
Angina pectoris 15 (94) 10 (77) 13 (93) 9 (90)
Grade 1 0 (0) 1 (8) 0 (0) 1 (10)
Grade 2 5 (31) 4 (31) 5 (36) 4 (40)
Grade 3 6 (38) 4 (31) 6 (43) 3 (30)
unknown 4 (25) 1 (8) 2 (14) 1 (10)
Previous myocardial infarction 7 (44) 8 (62) 5 (36) 6 (60)
Previous PCI 2 (13) 5 (39) 2 (14) 4 (40)
Hypertension 11 (69) 8 (62) 9 (64) 5 (50)
Hypercholesterolaemia 7 (44) 4 (31) 6 (43) 4 (40)
Ever smoked 11 (69) 9 (69) 11 (79) 7 (70)
Pack-year, mean (SD) 29 ± 14 34 ± 19 29 ± 14 39 ± 15
Family history IHD 6 (38) 6 (46) 6 (43) 4 (40)
COPD 2 (13) 1 (8) 2 (13) 1 (10)
Peripheral vascular disease 1 (6) 1 (8) 1 (7) 0 (0)
Cerebrovascular accident 0 (0) 1 (8) 0 (0) 1 (10)
Medication
Statins 16 (100) 13 (100) 14 (100) 10 (100)
β-blocker 13 (81) 11 (85) 11 (79) 8 (80)
ACE inhibitor 7 (44) 4 (31) 6 (43) 4 (40)
Diuretics 4 (25) 1 (8) 4 (29) 1 (10)
Nitrate 7 (44) 5 (39) 6 (43) 4 (40)
Coumarin derivatives 1 (6) 0 (0) 1 (7) 0 (0)
Clopidogrel 2 (13) 5 (39) 0 (0) 4 (40)
Carbasalate calcium/aspirin 16 (100) 11 (85) 14 (100) 9 (90)
PCI: Percutaneous Coronary Intervention; IHD: Ischaemic Heart Disease; COPD: Chronic Obstructive Pulmonary Disease. Values are presented as mean ± SD
or number (%)
Table 2 Intraoperative data
All patients Patients with mitochondria samples
Control (n = 16) RIPC (n = 13) Control (n = 14) RIPC (n = 10)
Bypass time (min) 109 ± 22 114 ± 42 110 ± 22 107 ± 17
Total cross-clamp time (min) 71 ± 17 72 ± 26 71 ± 17 67 ± 15
Number of grafts
One 1 (6) 0 (0) 1 (7) 0 (0)
Two 0 (0) 0 (0) 0 (0) 0 (0)
Three 7 (44) 5 (39) 7 (50) 4 (40)
Four 6 (38) 6 (46) 5 (36) 4 (40)
Five 2 (13) 2 (15) 1 (7) 2 (20)
Values are presented as mean ± SD or number (%)
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Confounders
One of the challenges in designing a clinical trial to
study the effects of RIPC is the selection of an anesthetic
protocol. Kottenberg et al. [4] observed that a cardiopro-
tective effect of RIPC did occur during isoflurane
anesthesia, but not during propofol anesthesia. In
addition, the same group observed that signal transducer
and activator of transcription 5 (STAT5) was activated
by RIPC during isoflurane anesthesia [20], but again not
during propofol anesthesia [21]. Also two recent large
multicenter clinical trials failed to show cardioprotection
using mainly propofol anesthesia [5, 6]. Although these
trials have been criticized for their use of propofol in-
stead of volatile anesthetics, effectiveness of RIPC with
volatile anesthetics only is not firmly based. Therefore,
we decided to examine RIPC cardioprotective effects in
sevoflurane-anaesthetized patients only. It should be
noted however, that patients in this study did receive
propofol after surgery. Continuation of hypnosis at the
end of surgery was achieved with propofol (on transport
to the ICU) and patients received propofol during mech-
anical ventilation for early ICU stay. Other studies did
not mention their anesthetic protocol employed after
surgery. It is conceivable that the exposure to propofol
early during reperfusion might have influenced the car-
dioprotective effect of RIPC in our current study. Al-
though human and animal studies have shown that
propofol anesthesia influences the effect of RIPC, the
important time window at which propofol inhibits the
cardioprotective effects of RIPC has not been studied.
Therefore, the early switch to propofol anesthesia might
have prevented the protective effect of RIPC. However, it
could not have affected the lack of differences in param-
eters measured before transport to the ICU.
Nevertheless, the use of volatile anesthetics could also
have masked a possible positive effect of RIPC. Volatile
anesthetics have been shown to be cardioprotective in
multiple studies [22, 23]. A recent meta-analysis of 15
randomized trials showed that volatile anesthetics can
influence cardioprotection by RIPC [9]. However, other
studies show cardioprotective effects of RIPC under
sevoflurane anesthesia in aortic valve replacement [24],
off-pump cardiac surgery [25] and complex valvular
heart surgery [26].
Furthermore, the use of a relatively high dose of mid-
azolam used in this study might have counteracted the
protective effects of RIPC. Midazolam has been shown
to abolish IPC in a rabbit study [27].
The use of opioids, like sufentanil in this study, has
been shown in both animal and human studies to pro-
tect the heart against IR injury [28]. This also could have
masked the effect of RIPC.
Taken together, many compounds used to anesthetize
the patient during surgery have either conditioning or
cardioprotective effects, or can antagonize the effects of
preconditioning. Since these compounds are necessary
to obtain proper anesthesia it is difficult to study the ef-
fect of RIPC alone in the CABG setting.
In addition to anesthesia, surgical conditions can affect
the effects of RIPC. Duration of ischemia is important in
preconditioning studies. If the ischemia is not long
enough, preconditioning has no beneficial effect and
preconditioning might not be strong enough after a too
long period of ischemia [29]. In a retrospective analysis
of their single-center clinical trial, Kleinbongard et al.
[30] found that a cross-clamp time of <56 min prevented
cardiac protection by RIPC. In our study, cross-clamp
time was comparable between groups and in both
groups only 4 patients had a cross-clamp time of
<56 min. It is therefore unlikely that a short cross-clamp
time has affected our results.
Furthermore, also patient characteristics and co-
medication might influence the effect of RIPC.
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Fig. 2 RIPC has no effect on cardiac troponin T levels. Cardiac
Troponin T (cTnT) levels over the 24 h perioperative period in
control and remote ischemic preconditioning (RIPC) treated
patients, measured before surgery and 6, 12 and 24 h after
surgery, were not different between control and RIPC treated
patients. AUC: Area under curve. Mean +/− SD Control n = 16,
RIPC n = 13
















Fig. 3 CRP levels are not altered by RIPC. No differences were
observed in C-reactive protein (CRP) levels over the 24 h perioperative
period between control and remote ischemic preconditioning (RIPC)
treated patients. CRP levels were measured before surgery and 6, 12
and 24 h after surgery. CRP: C-reactive protein. Mean +/− SD. Control
n = 16, RIPC n = 13





























































































Fig. 4 RIPC has no effect on mitochondrial hexokinase. The amount of mitochondrial bound hexokinase II (mtHKII) and HK activity were measured in
atrial tissue samples. Representative images of mtHKII/VDAC determined by western blot (a). HKII levels in mitochondria did not differ between control
and RIPC treated patients (b). No correlation between cTnT area under the curve (AUC) and mtHKII levels was observed (c). HK activity in
the mitochondria corrected for the amount of protein (d) or citrate synthase (CS) activity (e) did not differ between groups. mtHKII: mitochondrial
bound hexokinase II, HK: hexokinase, cTnT: cardiac troponin T, AUC: area under the curve, CS: citrate synthase. Single values and median (a and b) or
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Fig. 5 Survival proteins were not altered by RIPC. (p)AMPK and (p)Akt were analysed by Western blot in atrial tissue samples. Representative
images of pAMPK/AMPK (a) or pAKt/Akt (b) western blots. pAMPK/AMPK (c) and pAkt/Akt (d) levels were not changed by RIPC. Single values and
median (AMPK) or mean (Akt). Control n = 14, RIPC n = 10
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Antiplatelet drugs can reduce infarct size and prohibit fur-
ther cardioprotection by pre-or postconditioning [31, 32].
In our study antiplatelet drugs were continued until sur-
gery. This might have prevented a positive effect of RIPC.
Also angiotensin-converting enzyme (ACE) inhibitors can
reduce infarct size [33]. In addition, statins have been
associated with an increased protection by RIPC [8] and
β-blockers have been shown to attenuate RIPC induced
protection [9]. However, a retrospective analysis showed
no association between statins and β-blockers and protec-
tion by RIPC [30]. Furthermore, nicorandil use has been
shown to abolish ischemic preconditioning of the human
myocardium [34] and nicorandil users were therefor ex-
cluded from this study. Intraoperative use of nitroglycer-
ine had also been observed to interfere with RIPC [35].
This was however not confirmed in another study [30].
In animal studies diabetes mellitus has been shown to
abolish or diminish the effects of conditioning protocols
[36]. Results in human are contradictory [37, 38], and it
is suggested that not diabetes per se abolishes the pro-
tective effect of RIPC, but the use of sulphonylureas
does [37]. Of hypertension and hyperlipidemia it has
been shown that they interfere with conditioning [39].
Their role in RIPC is however still unknown. The pres-
ence of angina has been shown to protect against myo-
cardial infarction and can be considered as a form of
IPC [40]. Since most patients undergoing CABG have
angina, this might prohibit further protection by RIPC.
Also age and gender have been reported to influence
to effects of RIPC [41, 42] and is known to affect condi-
tioning in animal models [36, 43]. However, also this has
not been confirmed by retrospective analysis [8, 30]. To
reduce variation in our study, women were excluded.
It is impossible to take into account, and correct for,
all the factors mentioned above. Therefore, the effect of
RIPC can be abolished or diminished in some patients,
while others in the control group might already be con-
ditioned because of other reasons. This makes it difficult
to study the effects of RIPC and interpret the results. In
this study we tried to avoid many factors that could
interfere with the results. This, however lead very slow
inclusion rates, and sample size was not reached. In
addition, we cannot exclude that our neutral outcome
can be explained by any of the factors described above.
Survival proteins
The current paradigm for the end-effectors of cardiopro-
tection instigated by RIPC have been suggested to be in
part similar to those in IPC [41]. IPC has been shown to
increase the amount of mtHKII [12, 14] and the amount
of mtHKII is correlated with cardiac infarct size in a
genetic and environmental homogenous group of ani-
mals [12]. The amount of cardiac mtHKII may therefore
be viewed as a cardioprotective indicator. No changes in
mtHKII or activity with RIPC were observed in the
current study, thereby indirectly supporting the non-
beneficial RIPC effects on cTnT release. These findings
were corroborated that also no changes were detected in
the other cardiac survival proteins Akt and AMPK with
RIPC.
MIF
MIF is a pleiotropic inflammatory cytokine and is a me-
diator in several inflammatory diseases [44]. Ischemia
caused a release of MIF from the heart, which has been
shown to be cardioprotective by regulation of AMPK
signaling, inhibition of pro-apoptotic cascades and redu-
cing oxidative stress [45–47]. In CABG patients a peri-
operative increase in MIF was associated with enhanced
antioxidant capacity and reduced organ dysfunction after
cardiac surgery [47, 48]. We hypothesized that RIPC can
increase MIF. However, we did not observe any differ-
ences in serum MIF levels between control and RIPC
treated patient after RIPC, supporting the other observa-
tions of no effects of RIPC. It should be noted however,
that many values (25) were below the detection limit,
and lower than observed in other studies with CABG
patients [47, 48]. Therefore, these results should be
interpreted with care.
Inflammation
CRP is released during inflammation after tissue dam-
age. We have previously shown that tight glycemic con-
trol using continuous high doses of insulin in CABG
patients was associated with reduced CRP levels [49]. In
this study we used CRP levels as a second read-out, next
to cTnT levels, for cardiac damage caused by CABG sur-
gery. Since inflammation is a slower process, CRP and
cTnT levels should only be compared at later time












Fig. 6 Macrophage migration inhibitory factor is not different after
RIPC. Difference in macrophage migration inhibitory factor (MIF)
levels measured in blood before and after RIPC does not differ
between the control and RIPC treated group. Single values and
mean. Control n = 16, RIPC n = 13
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observe differences in CRP levels between control and
RIPC treated patients.
TNF-α, IL-6 and IL-10 have been shown to be able to
induce cardioprotection [50–52]. Therefore, we hypothe-
sized that RIPC triggers the release of these cytokines, to
establish the cardioprotective effect. To test this we
measured cytokine levels in serum samples before and
after RIPC. No differences in cytokine levels were ob-
served. Cai et al. [50] showed that late RIPC in mice was
associated with increased IL-10 levels and that the cardi-
oprotective effect of late RIPC was lost in IL-10 knock-
out mice, suggesting a promising role for IL-10 in RIPC
induced cardioprotection. However, other studies were
also unable to show a change in cytokines after IPC or
RIPC [3, 53, 54]. Cheung et al. [53] showed a non-
significant reduction in TNF-α levels 6 h postoperatively
in children receiving RIPC. However, no differences were
observed 3, 12 and 24 h postoperatively. Also no differ-
ences in IL-6, IL-8 or IL-10 were observed between con-
trols and RIPC treated subjects.
Limitations
Due to slow inclusion, the trial was stopped before tar-
get inclusion was reached. Using the number of patients
included and the 95% confidence interval, this study was
only able to state with 95% confidence that RIPC did not
reduce cTnT by > 27%. Nevertheless, it is our believe
that the 29 patients enrolled still provides valuable infor-
mation that can be used to obtain a more precise esti-
mate of RIPC efficacy (e.g. in meta-analysis), and should
be regarded as contribution to the topic of RIPC efficacy
in the setting of CABG procedures without the use of
propofol.
Conclusion
Due to the fact that the number of patients needed was
not reached within 3 years, the study was too underpow-
ered to draw any clear conclusion out of it. Nevertheless,
the results are not in line with previous studies in that
field, which makes it interesting and worth being dis-
cussed, but the small number of patients being included
makes the study itself failed for its primary goal, i.e. test-
ing whether RIPC decrease AUC cTnT by 25% in
propofol-anesthetized patients. In our explorative study
with limited number of patients, it is indicated that RIPC
under sevoflurane anesthesia does not reduce cTnT re-
lease by more than 27%. Together with our findings that
RIPC was without any effect on our secondary outcome
parameters reflecting possible cardioprotection, our
findings suggest that the absence of propofol is no guar-
antee for RIPC to result in more than 27% reduction in
cardiac damage, and that other factors than anesthesia
contribute to RIPC effectiveness.
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